These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 29734173)

  • 1. Soluble Urokinase Plasminogen Activator Receptor is Associated with Coronary Artery Calcification and Cardiovascular Disease in Patients Undergoing Hemodialysis.
    Wu W; Cui Y; Hu J; Liao R; Li S; Mo L; Xu L; Chen Y; Lian Z; Tian X; Li Z; Li R; Zhang L; Liang H; Ma J; Lin T; Feng Z; Dong W; Ke G; Ge P; Ye Z; Wang W; Zhang B; Shi W; Liang X; Liu S
    Kidney Blood Press Res; 2018; 43(3):664-672. PubMed ID: 29734173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble urokinase plasminogen activator receptor is associated with cardiovascular calcification in peritoneal dialysis patients.
    Guan J; Gong S; He Q; Wang X; Shen S; Wu X; Shan J; Gong T; Yang Y; Xie H
    Int Urol Nephrol; 2024 Jan; 56(1):191-198. PubMed ID: 37195572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting Mortality in African Americans With Type 2 Diabetes Mellitus: Soluble Urokinase Plasminogen Activator Receptor, Coronary Artery Calcium, and High-Sensitivity C-Reactive Protein.
    Hayek SS; Divers J; Raad M; Xu J; Bowden DW; Tracy M; Reiser J; Freedman BI
    J Am Heart Assoc; 2018 May; 7(9):. PubMed ID: 29716888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble urokinase plasminogen activator receptor is in contrast to high-sensitive C-reactive-protein associated with coronary artery calcifications in healthy middle-aged subjects.
    Sørensen MH; Gerke O; Eugen-Olsen J; Munkholm H; Lambrechtsen J; Sand NP; Mickley H; Rasmussen LM; Olsen MH; Diederichsen A
    Atherosclerosis; 2014 Nov; 237(1):60-6. PubMed ID: 25222341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease.
    Meijers B; Poesen R; Claes K; Dietrich R; Bammens B; Sprangers B; Naesens M; Storr M; Kuypers D; Evenepoel P
    Kidney Int; 2015 Jan; 87(1):210-6. PubMed ID: 24897037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of suPAR and hs-CRP on cardiovascular disease.
    Diederichsen MZ; Diederichsen SZ; Mickley H; Steffensen FH; Lambrechtsen J; Sand NPR; Christensen KL; Olsen MH; Diederichsen A; Grønhøj MH
    Atherosclerosis; 2018 Apr; 271():245-251. PubMed ID: 29402404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and prognostic usefulness of soluble urokinase plasminogen activator receptor in hemodialysis patients.
    Wlazeł RN; Szadkowska I; Bartnicki P; Rośniak-Bąk K; Rysz J
    Int Urol Nephrol; 2018 Feb; 50(2):339-345. PubMed ID: 29313168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study.
    Persson M; Engström G; Björkbacka H; Hedblad B
    Atherosclerosis; 2012 Feb; 220(2):502-5. PubMed ID: 22119508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardio-Renal Biomarker Soluble Urokinase-Type Plasminogen Activator Receptor Is Associated With Cardiovascular Death and Myocardial Infarction in Patients With Coronary Artery Disease Independent of Troponin, C-Reactive Protein, and Renal Function.
    Nikorowitsch J; Borchardt T; Appelbaum S; Ojeda F; Lackner KJ; Schnabel RB; Blankenberg S; Zeller T; Karakas M
    J Am Heart Assoc; 2020 Apr; 9(8):e015452. PubMed ID: 32299288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease.
    Mekonnen G; Corban MT; Hung OY; Eshtehardi P; Eapen DJ; Al-Kassem H; Rasoul-Arzrumly E; Gogas BD; McDaniel MC; Pielak T; Thorball CW; Sperling L; Quyyumi AA; Samady H
    Atherosclerosis; 2015 Mar; 239(1):55-60. PubMed ID: 25574858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble Urokinase-Type Plasminogen Activator Receptor and High-Sensitivity Troponin Levels Predict Outcomes in Nonobstructive Coronary Artery Disease.
    Al-Badri A; Tahhan AS; Sabbak N; Alkhoder A; Liu C; Ko YA; Vaccarino V; Martini A; Sidoti A; Goodwin C; Ghazzal B; Beshiri A; Murtagh G; Mehta PK; Quyyumi AA
    J Am Heart Assoc; 2020 Apr; 9(8):e015515. PubMed ID: 32301366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble Urokinase Plasminogen Activator Receptor and Outcomes in Patients with Diabetes on Hemodialysis.
    Drechsler C; Hayek SS; Wei C; Sever S; Genser B; Krane V; Meinitzer A; März W; Wanner C; Reiser J
    Clin J Am Soc Nephrol; 2017 Aug; 12(8):1265-1273. PubMed ID: 28495863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes.
    Samman Tahhan A; Hayek SS; Sandesara P; Hajjari J; Hammadah M; O'Neal WT; Kelli HM; Alkhoder A; Ghasemzadeh N; Ko YA; Aida H; Gafeer MM; Abdelhadi N; Mohammed KH; Patel K; Arya S; Reiser J; Vaccarino V; Sperling L; Quyyumi A
    Atherosclerosis; 2017 Sep; 264():108-114. PubMed ID: 28728756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SuPAR is associated with death and adverse cardiovascular outcomes in patients with suspected coronary artery disease.
    Hodges G; Lyngbæk S; Selmer C; Ahlehoff O; Theilade S; Sehestedt TB; Abildgaard U; Eugen-Olsen J; Galløe AM; Hansen PR; Jeppesen JL; Bang CN
    Scand Cardiovasc J; 2020 Dec; 54(6):339-345. PubMed ID: 32400206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes.
    Rotbain Curovic V; Theilade S; Winther SA; Tofte N; Eugen-Olsen J; Persson F; Hansen TW; Jeppesen J; Rossing P
    Diabetes Care; 2019 Jun; 42(6):1112-1119. PubMed ID: 30885954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble urokinase Plasminogen Activator Receptor (suPAR) mediates the effect of a lower education level on adverse outcomes in patients with coronary artery disease.
    Füller D; Liu C; Ko YA; Alkhoder AA; Desai SR; Almuwaqqat Z; Patel SA; Ejaz K; Kauser T; Martini MA; Alvi Z; Mehta PK; Sperling LS; Quyyumi AA
    Eur J Prev Cardiol; 2024 Mar; 31(5):521-528. PubMed ID: 37788634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex Differences in Circulating Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels and Adverse Outcomes in Coronary Artery Disease.
    Mehta A; Desai SR; Ko YA; Liu C; Dhindsa DS; Nayak A; Hooda A; Martini MA; Ejaz K; Sperling LS; Reiser J; Hayek SS; Quyyumi AA
    J Am Heart Assoc; 2020 Mar; 9(5):e015457. PubMed ID: 32089048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between Soluble Urokinase-Type Plasminogen Activator Receptor Levels and Chronic Kidney Disease: A Systematic Review and Meta-Analysis.
    Shuai T; Yan P; Xiong H; Huang Q; Zhu L; Yang K; Liu J
    Biomed Res Int; 2019; 2019():6927456. PubMed ID: 31886242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperfibrinolysis, uPA/suPAR system, kynurenines, and the prevalence of cardiovascular disease in patients with chronic renal failure on conservative treatment.
    Pawlak K; Buraczewska-Buczko A; Mysliwiec M; Pawlak D
    Am J Med Sci; 2010 Jan; 339(1):5-9. PubMed ID: 19926968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population.
    Eugen-Olsen J; Andersen O; Linneberg A; Ladelund S; Hansen TW; Langkilde A; Petersen J; Pielak T; Møller LN; Jeppesen J; Lyngbaek S; Fenger M; Olsen MH; Hildebrandt PR; Borch-Johnsen K; Jørgensen T; Haugaard SB
    J Intern Med; 2010 Sep; 268(3):296-308. PubMed ID: 20561148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.